Method for enzymatic treatment of tissue products

Patent metadata

Field	Value
Publication number	US-9956316-B2
Application number	US-201514924931-A
Country	US
Kind code	B2
Filing date	Oct 28, 2015
Priority date	Apr 28, 2011
Publication date	May 1, 2018
Grant date	May 1, 2018

Abstract

Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix.

First claim

What is claimed is:

1. A method for treating a tissue matrix, comprising:
selecting a dermal tissue matrix that does not contain epidermis;
treating the dermal tissue matrix with a first solution to remove substantially all cells and cellular components from the dermal tissue matrix; and
contacting the dermal tissue matrix with a second solution comprising a proteolytic enzyme under conditions sufficient to produce a desired level of pliability in the dermal tissue matrix and to increase the porosity of the dermal tissue matrix, wherein the enzyme is selected from bromelain, papain, ficin, actinidin, or combinations thereof.

2. The method of claim 1 , wherein the enzyme is bromelain.

3. The method of claim 1 , wherein the tissue matrix is contacted with the proteolytic enzyme under conditions that do not produce an undesirable change in at least one of tensile strength, tear strength, suture strength, creep resistance, burst strength, thermal transition temperature, or combinations thereof.

4. The method of claim 1 , wherein the tissue matrix is contacted with the proteolytic enzyme under conditions that do not cause a statistically significant reduction in tensile strength, tear strength, suture strength, creep resistance, thermal transition temperature, or combinations thereof.

5. The method of claim 1 , wherein the dermal tissue matrix comprises intact tissue.

6. A method for treating a tissue matrix, comprising:
selecting dermal acellular tissue matrix that does not contain epidermis; and
contacting the dermal acellular tissue matrix with a proteolytic enzyme under conditions sufficient to produce a desired level of pliability in the dermal acellular tissue matrix and to increase the porosity of the dermal acellular tissue matrix, wherein the enzyme is selected from bromelain, papain, ficin, actinidin, or combinations thereof.

7. The method of claim 6 , wherein the enzyme is bromelain.

8. The method of claim 6 , wherein the dermal acellular tissue matrix is contacted with the proteolytic enzyme under conditions that do not produce an undesirable change in at least one of tensile strength, tear strength, suture strength, creep resistance, burst strength, thermal transition temperature, or combinations thereof.

9. The method of claim 6 , wherein the dermal acellular tissue matrix is contacted with the proteolytic enzyme under conditions that do not cause a statistically significant reduction in tensile strength, tear strength, suture strength, creep resistance, thermal transition temperature, or combinations thereof.

Assignees

• Lifecell Corp

Inventors

• Chen Yi

Classifications

• A61P41/00

  Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61L27/3625

  Vascular tissue, e.g. heart valves · CPC title

• A61L27/56 Primary

  Porous materials, {e.g. foams or sponges} · CPC title